English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

There is tension between the need of the pharmaceuticalinnovator for intellectual property protectionand the need of society for equitable andaffordable access to innovative drugs. The recentAustralia?United States Free Trade Agreementprovides a nice illustration of this interplaybetween patents, pills and politics. This articleprovides a brief history of patent law as appliedto pharmaceuticals, describes how the PharmaceuticalBenefits Scheme got caught up in AUSFTAnegotiations, analyses the clauses that arelikely to impact upon the PBS and describes thepolitical process that reviewed and ultimatelyamended the AUSFTA.

Patents, pills and politics: the Australia–United States Free Trade Agreement and the Pharmaceutical Benefits Scheme